88 related articles for article (PubMed ID: 10022799)
21. The efficiency of simian foamy virus vector type-1 (SFV-1) in nondividing cells and in human PBLs.
Mergia A; Chari S; Kolson DL; Goodenow MM; Ciccarone T
Virology; 2001 Feb; 280(2):243-52. PubMed ID: 11162838
[TBL] [Abstract][Full Text] [Related]
22. Production of recombinant Herpesvirus saimiri-based vectors.
Whitehouse A
Cold Spring Harb Protoc; 2011 Dec; 2011(12):1515-9. PubMed ID: 22135662
[TBL] [Abstract][Full Text] [Related]
23. Tumor-selective gene transduction and cell killing with an oncotropic autonomous parvovirus-based vector.
Dupont F; Avalosse B; Karim A; Mine N; Bosseler M; Maron A; Van den Broeke AV; Ghanem GE; Burny A; Zeicher M
Gene Ther; 2000 May; 7(9):790-6. PubMed ID: 10822306
[TBL] [Abstract][Full Text] [Related]
24. A Herpesvirus saimiri-based vector expressing TRAIL induces cell death in human carcinoma cell lines and multicellular spheroid cultures.
Turrell SJ; Macnab SA; Rose A; Melcher AA; Whitehouse A
Int J Oncol; 2012 Jun; 40(6):2081-9. PubMed ID: 22396105
[TBL] [Abstract][Full Text] [Related]
25. Transient gene expression by nonintegrating lentiviral vectors.
Nightingale SJ; Hollis RP; Pepper KA; Petersen D; Yu XJ; Yang C; Bahner I; Kohn DB
Mol Ther; 2006 Jun; 13(6):1121-32. PubMed ID: 16556511
[TBL] [Abstract][Full Text] [Related]
26. Epstein-Barr virus vector-mediated gene transfer into human B cells: potential for antitumor vaccination.
Hellebrand E; Mautner J; Reisbach G; Nimmerjahn F; Hallek M; Mocikat R; Hammerschmidt W
Gene Ther; 2006 Jan; 13(2):150-62. PubMed ID: 16136164
[TBL] [Abstract][Full Text] [Related]
27. Specific oncolytic activity of herpesvirus saimiri in pancreatic cancer cells.
Stevenson AJ; Giles MS; Hall KT; Goodwin DJ; Calderwood MA; Markham AF; Whitehouse A
Br J Cancer; 2000 Aug; 83(3):329-32. PubMed ID: 10917547
[TBL] [Abstract][Full Text] [Related]
28. Lentiviral vectors transcriptionally targeted to hematopoietic cells by WASP gene proximal promoter sequences.
MartÃn F; Toscano MG; Blundell M; Frecha C; Srivastava GK; SantamarÃa M; Thrasher AJ; Molina IJ
Gene Ther; 2005 Apr; 12(8):715-23. PubMed ID: 15750617
[TBL] [Abstract][Full Text] [Related]
29. Selectable recombinant herpesvirus saimiri is capable of persisting in a human T-cell line.
Grassmann R; Fleckenstein B
J Virol; 1989 Apr; 63(4):1818-21. PubMed ID: 2538660
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of simian/human immunodeficiency virus replication in CD4+ T cells derived from lentiviral-transduced CD34+ hematopoietic cells.
Braun SE; Wong FE; Connole M; Qiu G; Lee L; Gillis J; Lu X; Humeau L; Slepushkin V; Binder GK; Dropulic B; Johnson RP
Mol Ther; 2005 Dec; 12(6):1157-67. PubMed ID: 16168713
[TBL] [Abstract][Full Text] [Related]
31. Gene-viral vectors: a promising way to target tumor cells and express anticancer genes simultaneously.
Qian Q; Sham J; Che X; Xu J; Xue H; Cui Z; Zhu B; Wu M
Chin Med J (Engl); 2002 Aug; 115(8):1213-7. PubMed ID: 12215295
[TBL] [Abstract][Full Text] [Related]
32. Resistance of human fibroblasts to c-fos mediated transformation.
Alt M; Grassmann R
Oncogene; 1993 Jun; 8(6):1421-7. PubMed ID: 8389028
[TBL] [Abstract][Full Text] [Related]
33. Development of human papillomavirus plasmids capable of episomal replication in human cell lines.
Sverdrup F; Sheahan L; Khan S
Gene Ther; 1999 Jul; 6(7):1317-21. PubMed ID: 10455442
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety analyses of a recombinant human immunodeficiency virus type 1 derived vector system.
Chang LJ; Urlacher V; Iwakuma T; Cui Y; Zucali J
Gene Ther; 1999 May; 6(5):715-28. PubMed ID: 10505094
[TBL] [Abstract][Full Text] [Related]
35. Transduction of human pancreatic tumor cells with vesicular stomatitis virus G-pseudotyped retroviral vectors containing a herpes simplex virus thymidine kinase mutant gene enhances bystander effects and sensitivity to ganciclovir.
Howard BD; Boenicke L; Schniewind B; Henne-Bruns D; Kalthoff H
Cancer Gene Ther; 2000 Jun; 7(6):927-38. PubMed ID: 10880025
[TBL] [Abstract][Full Text] [Related]
36. [Development of gene therapy for hematopoietic stem cell using viral vectors].
Dong WJ; Zu ZX; Liu DP; Liang CC
Yi Chuan Xue Bao; 2003 Apr; 30(4):382-8. PubMed ID: 12812066
[TBL] [Abstract][Full Text] [Related]
37. Assessment of infectivity using a Herpesvirus saimiri (HVS) recombinant that expresses HVS-GFP.
Whitehouse A
Cold Spring Harb Protoc; 2011 Dec; 2011(12):1520-3. PubMed ID: 22135663
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of adenoviral vectors by flow cytometry.
Weaver LS; Kadan MJ
Methods; 2000 Jul; 21(3):297-312. PubMed ID: 10873484
[TBL] [Abstract][Full Text] [Related]
39. Use of L-plastin promoter to develop an adenoviral system that confers transgene expression in ovarian cancer cells but not in normal mesothelial cells.
Chung I; Schwartz PE; Crystal RG; Pizzorno G; Leavitt J; Deisseroth AB
Cancer Gene Ther; 1999; 6(2):99-106. PubMed ID: 10195877
[TBL] [Abstract][Full Text] [Related]
40. Optimization of equine infectious anemia derived vectors for hematopoietic cell lineage gene transfer.
O'Rourke JP; Olsen JC; Bunnell BA
Gene Ther; 2005 Jan; 12(1):22-9. PubMed ID: 15550928
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
